Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Yosipovitch G, Lio PA, Rosmarin D, Serra-Baldrich E, Legat FJ, Casillas M, Pierce E, Liu Z, Sun L, Elmaraghy H, Ständer S. Yosipovitch G, et al. Among authors: stander s. Br J Dermatol. 2024 Jan 23;190(2):289-291. doi: 10.1093/bjd/ljad435. Br J Dermatol. 2024. PMID: 37939793 Clinical Trial. No abstract available.
Clinical aspects and management of chronic itch.
Zeidler C, Raap U, Witte F, Ständer S. Zeidler C, et al. Among authors: stander s. J Allergy Clin Immunol. 2023 Jul;152(1):1-10. doi: 10.1016/j.jaci.2023.04.018. Epub 2023 May 11. J Allergy Clin Immunol. 2023. PMID: 37178730 Review.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: stander s. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP, Bewley A, Ständer S, Castro C, Misery L, Kim BS, Biswas P, Chan G, Myers DE, Watkins M, Alderfer J, Güler E, Silverberg JI. Thyssen JP, et al. Among authors: stander s. Dermatology. 2024;240(2):243-253. doi: 10.1159/000535285. Epub 2023 Dec 11. Dermatology. 2024. PMID: 38081155 Free PMC article. Clinical Trial.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA, Kim BS, Hu X, Liu J, Calimlim BM, Vigna N, Crowley JT, Teixeira HD, Thyssen JP. Guttman-Yassky E, et al. Among authors: stander s. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2558-2568. doi: 10.1111/jdv.19391. Epub 2023 Aug 26. J Eur Acad Dermatol Venereol. 2023. PMID: 37528500 Clinical Trial.
Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial.
Fotheringham J, Guest J, Latus J, Lerma E, Morin I, Schaufler T, Soro M, Ständer S, Zeig S. Fotheringham J, et al. Among authors: stander s. Patient. 2024 Mar;17(2):203-213. doi: 10.1007/s40271-023-00668-1. Epub 2024 Jan 9. Patient. 2024. PMID: 38196014 Free PMC article. Clinical Trial.
487 results